Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short recovery skin renewal procedures, initially introduced in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to create a new treatment solution, further expanding the market coverage of existing device systems and enhancing their purchase and usage rates [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈推出PixelPeel™安全激光煥膚治療方案（「該方案」），旨在滿足對 安全、有效且恢復期短的皮膚煥新療程日益增長的需求，並全面運用在新一代 Alma Pixel™及Alma Hybrid設備系統中。該方案已於北美首發，並計劃逐步推向 全球市場。 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生及李家宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香 生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 PixelPeel™運用臨床公認的黃金標準激光能量，結合像素級精準度，並搭載Alma 專利MotionSync™技術，確保治療過程安全、 ...

复锐医疗科技(01696)再跌近5%，该股昨日重挫逾13%。截至发稿，跌4.81%，报5.74港元，成交额 1656.45万港元。 消息面上，复锐医疗科技日前发布2025年中期业绩，收益1.65亿美元，同比下降1.9%；母公司拥有人应 占溢利642.6万美元，同比下降41.3%。公告指出，期内集团收益同比减少，主要归因于北美市场状况充 满挑战，包括高利率及消费疲软。此外，六月因地区紧张局势令运输受限，导致收益确认略有延迟。若 不计北美市场不利因素，与2024年同期相比，复锐医疗科技国际市场实现7.1%增长。 申万宏源表示，公司北美市场受高利率及消费疲软冲击，收益下滑明显，拖累整体业绩；而北美以外国 际市场凭借直销办公室布局，实现7.1%增长。该行认为，作为能量源医美器械头部企业，公司依托直 销网络强化亚太优势，注射填充业务打开第二增长曲线。短期北美拖累不改长期逻辑，达希斐上市及联 合治疗生态放量有望驱动下半年业绩反弹。 ...

消息面上，复锐医疗科技日前发布2025年中期业绩，收益1.65亿美元，同比下降1.9%；母公司拥有人应 占溢利642.6万美元，同比下降41.3%。公告指出，期内集团收益同比减少，主要归因于北美市场状况充 满挑战，包括高利率及消费疲软。此外，六月因地区紧张局势令运输受限，导致收益确认略有延迟。若 不计北美市场不利因素，与2024年同期相比，复锐医疗科技国际市场实现7.1%增长。 申万宏源表示，公司北美市场受高利率及消费疲软冲击，收益下滑明显，拖累整体业绩；而北美以外国 际市场凭借直销办公室布局，实现7.1%增长。该行认为，作为能量源医美器械头部企业，公司依托直 销网络强化亚太优势，注射填充业务打开第二增长曲线。短期北美拖累不改长期逻辑，达希斐上市及联 合治疗生态放量有望驱动下半年业绩反弹。 智通财经APP获悉，复锐医疗科技(01696)再跌近5%，该股昨日重挫逾13%。截至发稿，跌4.81%，报 5.74港元，成交额1656.45万港元。 ...

Overall Performance - The company reported a revenue of 165 million USD for H1 2025, a year-on-year decrease of 2.5% [1] - The net profit attributable to the parent company was 6 million USD, down 41.3% year-on-year [1] - Gross margin stood at 60.0%, a decline of 2.4 percentage points year-on-year, while net margin was 5.4%, also down 2.4 percentage points [1] Regional Market Performance - Revenue from medical beauty products was 137.7 million USD, a decrease of 7.8% year-on-year, primarily affected by weak demand in the North American market [2] - Injection filling products generated 14.4 million USD, a significant increase of 218.1% year-on-year, driven by global direct sales and distribution networks [2] - North American revenue was 56.6 million USD, down 15.6% year-on-year, impacted by high interest rates and weak consumer spending [2] - Asia-Pacific revenue reached 65.8 million USD, up 17.6% year-on-year, benefiting from the effectiveness of the direct sales strategy [2] - European revenue was 23.8 million USD, a slight decline of 0.8% year-on-year [2] Product Development and Strategy - The company continues to optimize its product matrix, with core energy source devices like Soprano and Harmony maintaining competitiveness in hair removal and skin tightening [3] - The global first long-acting peptide-based neuromodulator Daxxify has received NMPA approval, and a sales team is being formed for its launch in China [3] - The company is advancing its pipeline with lipolytic injections completing Phase II clinical trials and other products like silk protein composite gel progressing [3] - The launch of AI-driven personalized skincare system Universkin and smart skin analysis platform Alma IQ is expected to enhance service value [3] - The company aims to leverage its direct sales network to strengthen its position in the Asia-Pacific region and open a second growth curve through injection filling business [3] - The company maintains profit forecasts, expecting net profits of 3.8 million USD, 4.6 million USD, and 5.4 million USD for 2025-2027, representing year-on-year growth of 52%, 21%, and 16% respectively [3]

上 市 公 司 医药生物 2025 年 08 月 21 日 复锐医疗科技 (01696) ——北美承压亚太增长，新品与渠道潜力待释放 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 08 月 21 日 | | --- | --- | | 收盘价（港币） | 6.03 | | 恒生中国企业指数 | 8974.77 | | 52 周最高/最低（港币） | 8.07/2.75 | | H 股市值（亿港币） | 28.24 | | 流通 H 股（百万股） | 468.34 | | 汇率（人民币/港币） | 1.0958 | 一年内股价与基准指数对比走势： -6% 94% 194% HSCEI 复锐医疗科技 资料来源：Bloomberg 相关研究 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 联系人 王盼 (8621)23297818× wangpan@swsresearch.com - 本研究报告仅通过邮件提供给 中庚基金 使用。1 公 司 研 究 / 公 ...

Sisram Medical (01696) H1 2025 Earnings Call August 21, 2025 08:30 AM ET Speaker0And so good afternoon and good evening. Thank you everyone for joining us today. Welcome to Sisram Medical's first half twenty twenty five earnings call. This is Jinpeng He from Citi Securities, and joining me today is our chief analyst, Yifan Du. So now I would like to introduce our speakers on the call.So with us today on the line are mister Yi Liu, Sisram's chairman mister Liu Daiyan, Sisram's chief executive officer and mis ...

Financial Performance - Sisram Medical's revenue decreased by 1.9% year-over-year to $165.5 million in H1 2025 [9, 71], but excluding North America, revenue grew 7.1% YoY [71] - Gross profit margin decreased by 2.4 percentage points to 60.0% [9, 71], due to product mix and decreased North America revenue [71] - Injectables revenue increased significantly by 218.1% year-over-year [9, 79], driven by geographical expansion and commercialization efforts [80] - Net profit decreased by 31.9% [70] Regional Performance - North America revenue decreased by 15.6% [10, 75] due to market headwinds [75] - APAC revenue increased by 17.6% [10, 75] due to the "Go-Direct" strategy [75] - Europe revenue declined slightly by 0.8% [75], but new EBD platforms saw notable growth [75] - Middle East and Africa revenue decreased by 9.7% [76] due to geopolitical tensions [76] Strategic Initiatives - The company is preparing for the launch of DAXXIFY in mainland China in H2 2025 [13, 45, 86] - The company is expanding global penetration of Alma Harmony, Alma IQ, and Universkin by Alma [86] - The company is driving injectables portfolio Revanesse and Profhilo growth in key markets [86] - The company is developing direct-sales offices in strategic regions [86]

Core Viewpoint - The financial report of Alma Medical Technology revealed a surprising decline in both revenue and profit, leading to a significant drop in stock price, marking the third consecutive day of decline [1][4]. Financial Performance - Revenue for the first half of 2025 was $165.5 million, a slight decrease of 1.9% year-on-year, primarily due to high interest rates in North America affecting consumer spending and geopolitical issues causing shipment delays in June [4][6]. - Net profit was $8.99 million, a substantial decline of 31.9% year-on-year, with adjusted net profit down 28.1% to $11.97 million, resulting in a net profit margin of 7.2% [4][5]. - Gross margin decreased from 62.5% in the same period last year to 60%, a drop of 2.4 percentage points [5]. Cash Flow and Liquidity - Operating cash flow showed a net outflow of $489,000, compared to a net inflow of $396,000 in the previous year, mainly due to increased working capital requirements (accounts receivable and inventory increased by approximately $30 million) [5]. - As of the end of the reporting period, cash and cash equivalents stood at $60.1 million, sufficient to cover short-term debts of $50.7 million, although liquidity is becoming tighter [5]. Business Segment Performance - The injection filling segment was a highlight, with revenue surging 218% due to the successful launch of Profhilo in Thailand and Revanesse in direct sales markets in the UK, Germany, and Australia [4][6]. - Revenue from energy source devices declined, with flagship products Harmony and Soprano series experiencing weak demand in North America, although the Asia-Pacific market continued to grow, partially offsetting the decline in Europe and the US [7]. Outlook - Despite the poor performance in the first half, the company is optimistic about the second half of 2025, expecting stronger revenue and profit driven by new orders [10][11]. - The company plans to focus on consolidating its leadership position in strategic growth regions, particularly in Asia-Pacific and North America, through direct sales expansion and targeted product launches [11].

复锐医疗科技(1696.HK)盘中大跌近13%，报6.1港元，为连续第三日下跌。消息面上，复锐医疗科技公 布，截至6月底止中期业绩，录得收益1.65亿美元，同比下降1.9%；纯利642.6万美元，同比跌41.3%； 每股盈利1.37美仙，不派息。 ...